Abstract:Antibiotic resistance has become a serious threat to public health, thus novel antibiotics are urgently needed to combat drug-resistant bacteria including MRSA (methicillin-resistant ). The 1,4-dicarbonylthiosemicarbazide is an interesting chemotype that could exhibit antibacterial activity. However, the currently available compounds are not as potent as clinical antibiotics. Herein, we adopted the computer-aided drug design strategy, substructure search, to retrieve antibacterial 1,4-dicarbonylthiosemicarbazide derivatives, and identified compound (Specs ID: AG-690/15432331) from the Specs chemical library that exhibited moderate activity (minimum inhibitory concentration (MIC): 6.25 µg/mL) against (ATCC 29213). Based on that compound, we further designed and synthesized 45 derivatives, and evaluated their antibacterial activity. Eight derivatives were more potent than or equivalent to vancomycin (MIC: 1.56 µg/mL). We compared the three most potent ones for their cytotoxicity to HepG2 and HUVEC cells and selected compound as our lead compound for comprehensive biological evaluation. As a result, compound exhibited a bacteriostatic mode, and was active against a panel of gram-positive bacteria strains, metabolically stable, and effective to protect the mice from MRSA infection. More importantly, we applied 2D similarity calculation and reverse docking to predict potential targets of compound . Through experimental validation and molecular dynamics simulation, we were able to confirm that compound inhibited DNA gyrase (IC : 1.81 µM) and DNA supercoiling, potentially by binding to the ATPase domain, where ASP81, GLU58 and GLN91 formed key hydrogen bonds. Taken together, we have discovered a new class of DNA gyrase inhibitors represented by compound for the treatment of MRSA infection, through the design, synthesis, and biological evaluation of novel 1,4-dicarbonylthiosemicarbazides.

What problem does this paper attempt to address?

This paper aims to solve the problem of treating infections caused by methicillin - resistant Staphylococcus aureus (MRSA). Specifically, the researchers hope to discover a new DNA gyrase inhibitor by designing, synthesizing and biologically evaluating new 1,4 - diketothiourea compounds to meet the challenge of antibiotic resistance. These 1,4 - diketothiourea compounds have potential antibacterial activity, but the activity of such compounds reported so far is not strong enough to be used as clinical antibiotics. Therefore, the goal of the study is to improve the antibacterial activity of such compounds through structural optimization and explore their mechanism of action, especially whether they can effectively inhibit DNA gyrase, thus providing new treatment options for MRSA infections. The key points of the paper include: 1. **Problem background**: Drug - resistant bacteria, especially MRSA, have become a major threat to public health, and there is an urgent need to develop new antibiotics to combat these resistant strains. 2. **Research objective**: Through computer - aided drug design strategies, screen out 1,4 - diketothiourea derivative B5 with moderate antibacterial activity from the chemical library, further design and synthesize 45 new derivatives, and evaluate their antibacterial activity. 3. **Main results**: Compound 1b was discovered, which shows good antibacterial activity against a series of Gram - positive strains and can protect mice from MRSA infection. More importantly, the potential target of compound 1b was predicted by 2D similarity calculation and reverse docking, and its inhibitory effect on Staphylococcus aureus DNA gyrase was verified experimentally (IC50: 1.81 μM), which may be achieved by binding to the ATPase domain, where ASP81, GLU58 and GLN91 form crucial hydrogen bonds. In conclusion, this study not only systematically explored the structure - activity relationship (SAR), but also verified the effectiveness and safety of new 1,4 - diketothiourea compounds through in vivo and in vitro experiments, providing an important scientific basis for the development of new anti - MRSA drugs.

Discovery of novel 1,4-dicarbonylthiosemicarbazides as DNA gyrase inhibitors for the treatment of MRSA infection

Design, synthesis, and biological evaluation of novel carbazole aminothiazoles as potential DNA-targeting antimicrobial agents

Synthesis and antibacterial activity of novel icariin derivatives.

Discovery of N-quinazolinone-4-hydroxy-2-quinolone-3-carboxamides As DNA Gyrase B-targeted Antibacterial Agents

<i>N</i>-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design, synthesis, biological evaluation and target identification

Computer-aided identification of novel 3,5-substituted rhodanine derivatives with activity against Staphylococcus aureus DNA gyrase.

An unexpected discovery toward novel membrane active sulfonyl thiazoles as potential MRSA DNA intercalators

Design, synthesis, and antibacterial evaluation of novel azolylthioether quinolones as MRSA DNA intercalators

Discovery, synthesis, and antibacterial activity of novel myrtucommulone analogs as inhibitors of DNA gyrase and topoisomerase IV

Novel potential artificial MRSA DNA intercalators: synthesis and biological evaluation of berberine-derived thiazolidinediones

Multi-Targeting Exploration of New 2-Aminothiazolyl Quinolones: Synthesis, Antimicrobial Evaluation, Interaction with Dna, Combination with Topoisomerase Iv and Penetrability into Cells

Synthesis, and Antibacterial Activity of Novel 4,5-Dihydro-1h-pyrazole Derivatives As DNA Gyrase Inhibitors.

Identification of promising anti-DNA gyrase antibacterial compounds using de novo design, molecular docking and molecular dynamics studies

Anti-MRSA drug discovery by ligand-based virtual screening and biological evaluation

Design, Synthesis, and Antimicrobial Evaluation of Novel Quinolone Imidazoles and Interactions with MRSA DNA

Discovery of novel dihydropyrrolidone-thiadiazole compound crosstalk between the YycG/F two-component regulatory pathway and cell membrane homeostasis to combat methicillin-resistant Staphylococcus aureus

Discovery and optimization of tetrahydroacridine derivatives as a novel class of antibiotics against multidrug-resistant Gram-positive pathogens by targeting type I signal peptidase and disrupting bacterial membrane

Ethylenic Conjugated Coumarin Thiazolidinediones As New Efficient Antimicrobial Modulators Against Clinical Methicillin-Resistant Staphylococcus Aureus.

Synthesis and Antimicrobial Evaluation of (Z)-5-((3-phenyl-1h-pyrazol-4- Yl)methylene)-2-thioxothiazolidin-4-one Derivatives

Discovery of new Schiff bases of the disalicylic acid scaffold as DNA gyrase and topoisomerase IV inhibitors endowed with antibacterial properties

Novel Organophosphorus Aminopyrimidines As Unique Structural DNA-targeting Membrane Active Inhibitors Towards Drug-Resistant Methicillin-Resistant Staphylococcus Aureus